Mabqi

Menu

Antibody-drug conjugates

Antibody-drug conjugates (ADCs) represent a promising class of anti-cancer therapeutics with significant therapeutic potential.

This innovative approach combines the targeting specificity of mAbs with the potent cytotoxicity of chemotherapeutic agents, offering improved efficacy and reduced systemic side effects compared to conventional chemotherapy.

Mabqi’s LiteMab Antibody Discovery Studio is well suited to support ADC discovery campaigns.

The company benefits from a strong track record through partnered programs and discovery campaigns:

  • Fully human antibody display libraries  to generate native antibodies or pH-sensitive antibodies
  • Dual technology platform (Phage-yeast display powered by AI): selection process optimized for rapid identification of best clones
  • Hits screening: hits characterization and screening. If initially requested, of pH-sensitive characteristic is confirmed (in vitro binding and kinetics)
  • Hits validation: functional assays such as internalization assays, epitope binning, in vitro cytotoxicity on target expressing cells, other assays on-demand.

Feel free to reach out to learn more on our expertise for ADC programs.